Deals have Slowed Down for Biotech M&A Tracker

Deals can be just as essential as scientific advances in the drug development industry. Without mergers and acquisitions, many of today’s most influential drugs, such as the life-saving cancer treatment Keytruda and the anti-inflammatory substance Humira, would not exist. Pharmaceutical M&A has reached new highs in recent years, as larger firms have increasingly looked to emerging biotechs for innovation.

These transactions were frequently focused on cancer, rare diseases, and immune system problems – areas of medical research where large triumphs in clinical trials and huge profits for therapies that made it to market were common. These bargains, on the other hand, haven’t come cheap. Biotech firms are finding it relatively easy to raise large sums of money from both private investors and the public markets.

That money may make them less open to buyout offers, forcing potential acquirers to make higher offers to get acquisitions. Premiums for biopharma acquisitions have frequently reached 100% in recent years. While mergers and acquisitions were bountiful in 2018 and 2019, and even held up throughout the coronavirus epidemic, 2021 has been considerably calmer. In fact, both the value and volume of biopharma Deals fell to five-year lows in the second quarter.

Whether or not this pattern continues or reverts to pre-pandemic levels of activity will have a big impact on which therapeutic programmes are financed and advanced. These Deals are being tracked by BioPharma Dive. The database, which includes drugmaker purchases for $50 million or more in upfront consideration that occurred during 2018, will be updated on a regular basis. To learn more about an acquiring firm, click on its name and scroll down to the bottom of the page to see how the data was gathered and organised.